To evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.
A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease
Who may be eligible to participate?
Male and female, 50 to 85 years of age, who were diagnosed with Parkinson's Disease within the last 6 months to 3 years at screening visit. Other exclusion criteria apply.
What does participation involve?
This study will consist of the following phases: screening, double-blind treatment, and safety follow-up. Participants who meet eligibility criteria will be randomly assigned (in a 1:1 ratio) in a blinded fashion to receive either placebo or the investigational treatment via intravenous infusion. The study duration will be at least 76 weeks for all participants.